Themes
Business
Talent
At the park
Communities
Jobs & internships
Events
News
Contact
Researchers at Leiden University Medical Center (LUMC), in collaboration with Erasmus MC and the Oncode Institute, have developed a novel vaccine targeting non-small cell lung cancer (NSCLC). This vaccine aims to expose cancer cells that have evaded the immune system, potentially enhancing the effectiveness of immunotherapy treatments.
In a preliminary clinical study involving 26 patients with advanced NSCLC, the vaccine demonstrated safety and elicited an immune response in over 80% of participants. The vaccine works by training immune cells to recognize a specific protein, TEIPP, present only on cancer cells that have become invisible to the immune system. By making these hidden cells detectable again, the immune system can more effectively target and destroy them.
While these initial results are promising, further research is needed to determine the vaccine’s impact on tumor reduction and patient survival. Future studies will explore optimal dosing schedules and the potential benefits of combining the vaccine with existing immunotherapies.
This approach highlights the collaborative efforts within the Leiden Bio Science Park to advance cancer treatment through innovative research.
Read more here: https://www.lumc.nl/actueel/2025/vaccin-tegen-longkanker/
A new research collaboration between TNO, Logick Energetics B.V., and InnoSer has officially kicked off at Leiden Bio Science Park, supported by a TKI-LSH grant. The partners...
The Faculty of Science at Leiden University is offering a new opportunity for professionals to deepen their knowledge of data-driven decision-making, complex systems, and...
𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟭𝟱 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗽𝗲𝗻 𝘁𝗵𝗲𝗶𝗿 𝗱𝗼𝗼𝗿𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰? You get an Open Day that brings together over 2,400 visitors, families, students,...